EUVIMEDEUVIMED entdecken
EditorialKommentar

Savings Associated With “Skinny Label” Biosimilars

Eric Ward, Robert Steinbrook

JAMA Internal Medicine · 2023

DOI: 10.1001/jamainternmed.2022.5418 ↗

Kurz gefasst

Editorial in der Zeitschrift JAMA Internal Medicine, 2023. Verfasst von Eric Ward und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsHumansDrug ApprovalCost SavingsIncome

Substanzen

Biosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Francisco.
  • Editorial Fellow, JAMA Internal Medicine.
  • Editor at Large and Online Editor, JAMA Internal Medicine.

Zitieren

APA

Ward, E., & Steinbrook, R. (2023). Savings Associated With “Skinny Label” Biosimilars. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2022.5418

Vancouver

Ward E, Steinbrook R. Savings Associated With “Skinny Label” Biosimilars. JAMA Internal Medicine. 2023. doi:10.1001/jamainternmed.2022.5418

BibTeX
@article{Ward2023,
  author = {Ward, Eric and Steinbrook, Robert},
  title = {Savings Associated With “Skinny Label” Biosimilars},
  journal = {JAMA Internal Medicine},
  year = {2023},
  doi = {10.1001/jamainternmed.2022.5418}
}
Kostenlos starten →